Acorda Therapeutics (ACOR) has acquired the rights in the Americas and certain other territories...

|About: Acorda Therapeutics, Inc. (ACOR)|By:, SA News Editor

Acorda Therapeutics (ACOR) has acquired the rights in the Americas and certain other territories to two nerve pain treatments from NeurogesX (NGSX.OB) - FDA approved Qutenza and "Phase III ready" NP-1998. Acorda paid $8M up front and will pay as much as $5m in milestones related to NP-1998. (PR)